Though BRD9 expression does not change with increases in Gleason grade and tumour stage, its expression was higher in metastatic PCa when compared to cancer-free patients and patients with local disease, suggesting that BRD9 could play a role as a prognostic biomarker and therapeutic target, especially in metastatic PCa. The gene discussed is BRD9; the disease is cancer.